Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin US09062X1037
Ticker BIIB
Company BIOGEN
Currency $
Price
Aware Investor Index (AII) 2.3279
Recommendation BUY
P/E 24.84
ROE 18.10 %
Capitalization 58,650,104,000 $
Dividend Yield 0.00 %
P/S 4.36
AII Position 200
P/E Position 356
ROE Position 185
Capitalization Position 164
Dividend Yield Position 597
Sales 13,452,900,000 $
10-Year Average Earnings 2,360,650,000 $
Shares Outstanding 205,300,000
Equity 13,039,600,000 $
Dividend per Share 0 $
Industry Biotechnology
Country United States
BIOGEN Investor Relations Web Site http://investors.biogen.com/investor-relations







Sales:

YEAR MONTH AMOUNT
2018 12 13,452,900,000.00 $
2017 12 12,273,900,000.00 $
2016 12 11,448,800,000.00 $
2015 12 10,763,800,000.00 $
2014 12 9,703,300,000.00 $
2013 12 6,932,200,000.00 $
2011 12 5,516,500,000.00 $
2010 12 5,048,600,000.00 $
2009 12 4,716,400,000.00 $
2008 12 4,377,300,000.00 $

Earnings:

YEAR MONTH AMOUNT
2018 12 4,430,700,000.00 $
2017 12 2,539,100,000.00 $
2016 12 3,702,800,000.00 $
2015 12 3,547,000,000.00 $
2014 12 2,934,800,000.00 $
2013 12 1,862,300,000.00 $
2012 12 1,380,000,000.00 $
2011 12 1,234,400,000.00 $
2010 12 1,005,300,000.00 $
2009 12 970,100,000.00 $

Equity:

YEAR MONTH AMOUNT
2018 12 13,039,600,000.00 $
2017 12 12,612,800,000.00 $
2016 12 12,140,000,000.00 $
2015 12 9,372,800,000.00 $
2014 12 10,809,000,000.00 $
2013 12 8,620,200,000.00 $
2012 12 6,961,500,000.00 $

Shares Outstanding:

YEAR MONTH AMOUNT
2018 12 205,300,000
2017 12 213,000,000
2016 12 218,800,000
2015 12 231,200,000
2014 12 237,200,000
2013 12 238,300,000
2012 12 239,700,000

 












Bloomberg News for BIOGEN:



Google News for BIOGEN:

Seeking Alpha - 3 days ago
Sell Biogen Going Into Its Aducanumab BLA Filing
Biogen's (BIIB) Aducanumab under investigation for the treatment of dementia in Alzheimer's disease has seen a stunning reversal after a ...
Polson News - 9 hours ago
Mengis Capital Management Inc. Grows Stock Holdings in Biogen ...
Mengis Capital Management Inc. grew its holdings in shares of Biogen Inc (NASDAQ:BIIB) by 7.3% in the 3rd quarter, Holdings Channel.com ...
Mitchell Messenger
Here's Why Biogen Stock Shot Up 28% in October
Shares of Biogen (NASDAQ:BIIB), a giant biopharmaceutical operation, jumped after management told investors the company would reboot ...
Antony Press
Biogen (BIIB) Q3 Earnings & Sales Beat Estimates
Cambridge, MA-based Biogen Inc. BIIB holds a strong position in the multiple sclerosis (“MS”) market with a wide range of products including ...
Riverton Roll
Biogen Is A Buy Regardless Of Aducanumab
Biogen (BIIB) has been on even more of a roller-coaster ride than the rest of the highly volatile biotechnology pharmaceutical sector this year.
Motley Fool - 1 day ago
Biogen's Alzheimer's Drug Goes From Bust to Boon, Plus Why ...
Biogen's (NASDAQ:BIIB) drug pipeline took a massive hit earlier this year when the company stopped development of its Alzheimer's disease ...
Slater Sentinel
Watch List Stock Performance:: Biogen Inc., (NASDAQ: BIIB)
On Friday, November 08, 2019, the Company, Biogen Inc., BIIB stock construct a change of 2.22 percent (↑ / Gain) in a total of its share price ...
Mitchell Messenger
Biogen (BIIB) to Report Q3 Earnings: What's in the Cards?
Biogen Inc. BIIB is set to report third-quarter 2019 results on Oct 22, before market open. In the last reported quarter, the company delivered a ...
Riverton Roll
With high stakes, eight experts would wield extraordinary influence ...
Biogen (BIIB 5) is planning to seek Food and Drug Administration approval 6 for a once-disregarded drug, and if everything goes according to ...
Nasdaq - 22 Oct 2019
Stock Recap:: Biogen (NASDAQ:BIIB)
Biogen (NASDAQ:BIIB) STOCK IN FOCUS: Overbought and Oversold levels. The stock has RSI reading of 70.37. RSI gives an indication of the ...


Back